Artiva Biotherapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Artiva Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $7.00K.
- Artiva Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $131.00K, a 2.24% decline year-over-year.
- Artiva Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $99.00K.
- Artiva Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $134.00K.
- Artiva Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $233.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $7.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $131.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $233.00K 10-K · filed 2026-03-10 | |
| 2025-09-30 | $99.00K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $134.00K 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |